Allogene Therapeutics Announces Participation in March Investor Conference

Company Overview - Allogene Therapeutics, Inc. is a clinical-stage biotechnology company based in South San Francisco, focusing on the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases [2] - The company aims to create a pipeline of "off-the-shelf" CAR T cell product candidates to provide readily available cell therapy on-demand, more reliably, and at greater scale to a larger patient population [2] Upcoming Events - Allogene Therapeutics will participate in the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 8:20 AM PT / 11:50 AM ET [1] - Webcasts of the conference will be available on the company's website, with replays accessible for approximately 30 days [1]